...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Combo with Enzalutamide in Phase 2 Metastatic Prostate Cancer Clinical Trial and with Pfizer’s PARPi, talazoparib, in Phase 1b/2 Triple Negative Breast Cancer Trial

Free
AGORACOM NEWS FLASH

BREAKING:  Hollister Biosciences Provides Update on Q2 2020, Generated Record Quarterly Revenue of CDN$ 11.5 Million

  • CDN$ 1.375 million in EBITDA
  • Bureau of Cannabis Control officially renewed its cannabis distribution license for the next year through August 2021
  • "We are very pleased with our revenue growth year to date.  Sales of cannabis related products have proven to be resilient throughout the COVID-19 pandemic.  We hope to continue to deliver strong results as the year progresses" stated Carl Saling, CEO.

Hollister large

Hub On AGORACOM / Read Release

Zenith Epigenetics Stock Quotes

For access to level II stock quotes, you must have attained an Agoracom ranking of at least Treasurer.